Selectively inhibits protein kinase C (PKC)-induced activation of the NF-κ
B pathway (IC50
< 0.1 μ
M for PMA
-stimulated IL-8 production). Inhibits antigen receptor-stimulated NF-κ
B activation in chronic lymphocytic leukemia (CLL) B cells. Does not inhibit other NF-κ
B pathways, including that activated by tumor necrosis factor (TNF).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Inhibition of protein kinase C-driven NF-κB activation: synthesis, SAR, and pharmacological profiling of pathway specific benzimidazole probe molecules.
Peddibhotla et al.
Chemical biology strategy reveals pathway-selective inhibitor of NF-κB activation induced by protein kinase C and antigen receptors.
Shi et al.
ACS Chem.Bio., 2010;5:287